论文信息 - BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population - 字舞流文

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

K. Tamura | C. Corcoran | G. Schiavon | B. Davies | N. Turner | M. Sablin | J. Pérez-Fidalgo | E. D. de Bruin | A. Armstrong | Mafalda Oliveira | S. Cheung | M. Moschetta | R. Maudsley | J. Lindemann | P. Rugman | M. Pass | M. Cullberg | E. Alarcón | E. D. Bruin | A. Foxley | M. Philco | M. Oliveira | A. Villanueva | Y. A. López Chuken | A. Gómez Villanueva | E. Outhwaite | Nicholas C Turner | Y. L. Chuken